More Access and Evidence Articles

Access and Evidence

The Price Of Access

Lucy Fulford, (Nov 13, 2017)

With tight purse strings right across the world, innovative pricing schemes are a crucial step in delivering affordable healthcare
Access and Evidence

A Bright Future

Lucy Fulford, (Nov 9, 2017)

Innovation is disrupting the entire healthcare continuum, creating opportunities for Medical Affairs in new and exciting places, says BMS’ Lav Parvathenani.
Access and Evidence

Surfing The Data Tsunami

Danielle Barron, (Nov 8, 2017)

How pharma is working together with government, regulators, tech companies and their industry peers to establish a strong foundation for health data across Europe
Access and Evidence

Under Pressure

Hugh Gosling, (Oct 31, 2017)

Pharma must lay its cards on the table and build a more transparent relationship with payers
Access and Evidence


Hugh Gosling, (Oct 26, 2017)

An expert powerhouse involved in key strategic decisions right across the lifecycle, Market Access has come a long way in a short time
Access and Evidence

A Change Is Coming

Danielle Barron, (Oct 9, 2017)

Health technology assessment is building up steam in the US – and pharma needs to prepare for it
Access and Evidence

Pragmatic Trials: The Real-World Data Revolution

Adam Chapman, (Sep 27, 2017)

Insights derived from real-world data are changing every facet of pharma but its impact on clinical trials may prove to be a crowning achievement
Access and Evidence

Indication-Based Pricing: A Utopian Ideal?

Adam Chapman, (Sep 11, 2017)

The potential benefits of moving to a variable pricing model based on indication are manifold, but is the US healthcare system ready?
Access and Evidence

Thinking Outside The Box

Adam Chapman, (Sep 5, 2017)

In digital, it’s all about personalization. Isn’t it time pharma caught up with other industries?
Access and Evidence

Finding Common Ground: Australian Government Seeks Closer Ties With Pharma

Adam Chapman, (Aug 30, 2017)

The Australian government asks for pharma’s help to ensure patients gain fast access to new medicines